Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

Stefania Tognin, Hendrika H van Hell, Kate Merritt, Inge Winter-van Rossum, Matthijs G Bossong, Matthew J Kempton, Gemma Modinos, Paolo Fusar-Poli, Andrea Mechelli, Paola Dazzan, Arija Maat, Lieuwe de Haan, Benedicto Crespo-Facorro, Birte Glenthøj, Stephen M Lawrie, Colm McDonald, Oliver Gruber, Therese van Amelsvoort, Celso Arango, Tilo KircherBarnaby Nelson, Silvana Galderisi, Rodrigo Bressan, Jun S Kwon, Mark Weiser, Romina Mizrahi, Gabriele Sachs, Anke Maatz, René Kahn, Phillip McGuire, PSYSCAN Consortium

Research output: Contribution to journalJournal articlepeer-review

56 Citations (Scopus)
55 Downloads (Pure)

Abstract

In the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.

Original languageEnglish
JournalSchizophrenia Bulletin
Volume46
Issue number2
Pages (from-to)432-441
Number of pages10
ISSN0586-7614
DOIs
Publication statusPublished - 2020

Cite this